[Platelet aggregation during adjuvant chemotherapy with CMF].
We have studied platelet aggregation in fourteen pre- and post-menopausal women treated with cyclic adjuvant CMF chemotherapy for mammary cancer with positive axillary nodes, previously operated. Aim of the investigation is to evaluate the effect of chemotherapy on platelet aggregation. The obtained results demonstrate that CMF therapy does not modify platelet aggregation in both pre- and post-menopausal patients.
Sbalzarini
G
G
I Divisione Medica, USSL n. 56, Ospedale Maggiore di Lodi.
Pandolfi
C
C
Labadini
A
A
D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy; D002288:Adenocarcinoma, Mucinous / Q000097:blood / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy; D002277:Carcinoma / Q000097:blood / Q000188:drug therapy; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000097:blood / Q000188:drug therapy; D002291:Carcinoma, Papillary / Q000097:blood / Q000188:drug therapy; D003520:Cyclophosphamide / Q000009:adverse effects; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects; D006801:Humans; D008593:Menopause; D008727:Methotrexate / Q000009:adverse effects; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*
D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate
L'aggregazione piastrinica in corso di chemioterapia precauzionale con "CMF".